Neurodegenerative Diseases: World Drug Market 2011-2026

Date: November 1, 2010
Pages: 182
Price:
US$ 2,325.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N50118ED4E3EN
Leaflet:

Download PDF Leaflet

Neurodegenerative Diseases: World Drug Market 2011-2026
Would you like to know how the industry and market for neurodegenerative drug treatments will develop? There will be trends to watch from 2010 onwards, especially areas of revenue growth. You can have our new report now, staying ahead, saving time and aiding your decisions.

The number of patients may quadruple worldwide by 2050. Yet, there remain significant unmet needs in all sectors of the neurodegenerative treatments market.

You can assess those commercial opportunities now, with us providing forecasts for the following drug markets from 2010 to 2026:
  • Multiple sclerosis
  • Alzheimer's disease
  • Parkinson's disease
  • Neuropathies
  • Huntington's disease
  • Amyotrophic lateral sclerosis.

Our new report analyses and discusses strengths, weaknesses and revenue trends of the sector from 2009 to 2026.

All sectors of the market have been expanding, but which will fare best from 2010 onwards? How will those submarkets, and the overall market sector, cope with patent expiries this decade? How will leading national markets perform from 2010 to 2026? What opportunities are there for resolving unmet therapeutic needs?

We show you where the neurodegenerative drug treatment sector is heading. Our report shows you its technological and commercial potential, revealing opportunities, challenges and requirements for success there.

New drugs with improved safety and efficacy can gain significant market shares from 2010 onwards. There remain high revenues to be made in this sector from 2010 to 2026, as we show and explain.

New treatment types - such as oral agents for MS - could re-shape the market from this decade onwards. There will be commercial growth, with important trends to watch.

We show how you could make gains there. Our report makes it quick and practical for you to assess the potential of the industry and market now.

Analysis and expert views to aid your work - so you won't be left behind

Our new report provides you with revenue forecasts, market share analyses, R&D pipeline developments and expert opinion. That way, you can assess prospects, opportunities and threats in the sector. It is that combination of data that sets us apart.а

We include 98 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas.

World Neurodegenerative Diseases: World Drug Market 2011-2026 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
  • You will receive hard data for the neurodegenerative diseases sector - especially our revenue forecasts - helping you to stay ahead
  • You will discover revenue trends for the overall market and its main components from 2009 to 2026 - showing you where commercial potential will lie
  • You will find revenue predictions for leading national markets from 2009 to 2026 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
  • You will learn how the sector can change and adapt from 2010 to 2026
  • You will assess leading organisations in neurodegenerative disease treatment, discovering their activities and prospects
  • You will discover the drivers, restraints, competition and opportunities influencing this sector, including oral agents for MS, outcomes of research and drug targets
  • You will investigate unmet and under-met needs in that sector, with therapeutic requirements and commercial opportunities discussed
  • You will review R&D pipelines, assessing the potential of developments
  • You will view expert opinion from our survey, including interview transcripts
  • You will find out where the sector is heading - technology, competition, revenues and other aspects of the industry and market.
1. EXECUTIVE SUMMARY

1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. NEURODEGENERATIVE DISEASES: AN INTRODUCTION

2.1 What Are Neurodegenerative Diseases?
2.2 Multiple Sclerosis (MS)
  2.2.1 Treatment Options
2.3 Alzheimer's Disease
  2.3.1 Treatment Options
2.4 Parkinson's Disease
  2.4.1 Treatment Options
2.5 Neuropathies
  2.5.1 Neuropathic Pain
  2.5.2 Treatment Options
    2.5.2.1 Pharmacological Treatments
2.6 Huntington's Disease
  2.6.1 Treatment Options
2.7 Amyotrophic Lateral Sclerosis (ALS)
  2.7.1 Treatment Options

3. WORLD NEURODEGENERATIVE DISEASES DRUG MARKET 2009-2026

3.1 Analysis of the Market in 2009
  3.1.1 A Market Dominated by Blockbusters
3.2 Neurodegenerative Diseases: Market Forecast 2010-2026
  3.2.1 Market Forecast 2010-2016
  3.2.2 Blockbuster Patent Expiries
  3.2.3 Symptom Treatment over Disease Modification
  3.2.4 Market Forecast 2016-2026
    3.2.4.1 Rapid Growth in Smaller Markets

4. MULTIPLE SCLEROSIS (MS) MARKET

4.1 Treatment Available for MS
  4.1.1 Treatment for Symptoms
  4.1.2 Disease-Modifying Medicines
4.2 MS Market in 2009
4.3 MS Market Forecast 2010-2026
  4.3.1 Market Forecast 2010-2016
  4.3.2 Market Forecast 2016-2026
  4.3.3 Oral Treatments
  4.3.4 An Approval Pathway for Biosimilars
4.4 Copaxone
  4.4.1 Copaxone Sales Forecast 2010-2026
  4.4.2 Patent Expiry and Competition
4.5 Avonex
  4.5.1 Avonex Sales Forecast 2010-2016
  4.5.2 Avonex Long-Term Forecast 2016-2026
4.6 Rebif
  4.6.1 Rebif Sales Forecast 2010-2016
  4.6.2 Rebif Will Be Challenged Beyond 2016
4.7 Betaferon
  4.7.1 Betaferon and Generic Competition
4.8 Tysabri
4.9 MS Pipeline Analysis
  4.9.1 Oral Treatments
  4.9.2 Monoclonal Antibodies
  4.9.3 Vaccines

5. ALZHEIMER'S DISEASE MARKET

5.1 There Are Only Five Drugs Approved for Treating Alzheimer's
5.2 Analysis of the Market in 2009
5.3 Alzheimer's Market Forecast 2010-2026
  5.3.1 Market Forecast 2010-2016
  5.3.2 Market Forecast 2016-2026
5.4 Aricept
  5.4.1 Aricept Sales Forecast 2010-2026
5.5 Namenda
  5.5.1 Namenda Sales Forecast 2010-2026
5.6 Exelon
  5.6.1 Exelon Sales Forecast 2010-2026
5.7 Alzheimer's R&D Pipeline: Analysis
  5.7.1 Gamma Secretase Inhibitors
    5.7.1.1 Tau Inhibitors
  5.7.2 Immunotherapy
    5.7.2.1 Monoclonal Antibodies
    5.7.2.2 IVIg
  5.7.3 Amyloid-? Detection

6. PARKINSON'S DISEASE MARKET

6.1 Parkinson's Market in 2009
6.2 Parkinson's Market Forecast 2010-2026
6.3 Sifrol
  6.3.1 Sifrol Sales Forecast 2010-2026
6.4 Stalevo & Comtess
  6.4.1 Stalevo for Early Stage Parkinson's
  6.4.2 Stalevo & Comtess Sales Forecast 2010-2026
6.5 Requip
  6.5.1 Requip Sales Forecast 2010-2026
6.6 Azilect
  6.6.1 Azilect Delays Disease Progression
  6.6.2 Azilect Sales Forecast 2010-2026
6.7 Future Therapy for Parkinson's
  6.7.1 Developments for Levodopa
  6.7.2 KW-6002
  6.7.3 Safinamide
  6.7.4 Gene Therapy Could Soon Be a Treatment Option
    6.7.4.1 Ceregene
    6.7.4.2 Neurologix
  6.7.5 Long-Term Treatment Options

7. NEUROPATHIES MARKET

7.1 Treatment Options
  7.1.1 Anticonvulsants
  7.1.2 Analgesics
    7.1.2.1 Local Anaesthetics
  7.1.3 Antidepressants
  7.1.4 Aldose Reductase Inhibitors
    7.1.4.1 Kinedak
7.2 Neuropathy Market in 2009
7.3 Neuropathy Market Forecast 2010-2026
  7.3.1 Market Forecast 2010-2016
  7.3.2 Market Forecast 2016-2026
  7.3.3 Neurontin: The Forerunner of Lyrica
  7.3.4 Qutenza is a Recently-Approved Neuropathy Treatment
7.4 Lyrica Sales Forecast 2010-2026
  7.4.1 Lyrica Patents Expire in 2013 and 2018
7.5 Future Treatment of Neuropathies
  7.5.1 AS-3201
  7.5.2 KRN5500
  7.5.3 Epicept NP-1
  7.5.4 Secondary Indication Drugs
  7.5.5 J&J and Monoclonal Antibodies

8. HUNTINGTON'S DISEASE MARKET

8.1 Huntington's Market in 2009
8.2 Huntington's Market Forecast 2010-2026
8.3 Xenazine
  8.3.1 Xenazine Sales Analysis, 2009
  8.3.2 Xenazine Sales Forecast 2010-2026
8.4 R&D Pipeline Analysis
  8.4.1 Huntexil
  8.4.2 Dimebon
  8.4.3 Antioxidant Therapy
  8.4.4 RNAi as a Potential Treatment

9. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET

9.1 ALS Market in 2009
9.2 ALS Market Forecast 2010-2026
  9.2.1 ALS Market Forecast: Best Case Scenario
  9.2.2 ALS Market Forecast: Worst Case Scenario
9.3 Rilutek
  9.3.1 Rilutek Sales Forecast 2010-2026
9.4 R&D Pipeline Analysis
  9.4.1 Olesoxime
  9.4.2 Mecobalamin
  9.4.3 Radicut
  9.4.4 Dexpramipexole

10. LEADING NATIONAL MARKET FORECASTS 2010-2026

10.1 US Market: Forecast 2010-2026
10.2 Leading European Markets: Forecasts 2010-2026
10.3 Japanese Market: Forecast 2010-2026
10.4 Leading Emerging Markets: Forecasts 2010-2026
  10.4.1 China
  10.4.2 India

11. ISSUES AFFECTING THE NEURODEGENERATIVE DISEASES MARKET 2010-2026

11.1 SWOT Analysis of the Neurodegenerative Diseases Market 2010-2026
11.2 Strengths
  11.2.1 Neurodegenerative Diseases Are High Profile
  11.2.2 Chronic Diseases: Long-Term Repeat Sales
11.3 Weaknesses
  11.3.1 Side Effects Associated with Treatment
  11.3.2 The High Costs of Treatment
  11.3.3 High Product Competition
11.4 Opportunities
  11.4.1 Significant Unmet Needs Still Exist in the Market
  11.4.2 Aging Populations Will Lead to Increased Disease Prevalence
  11.4.3 Orphan Status and Fast Track Reviews for New Drugs
11.5 Threats
  11.5.1 Patent Expiries Will Lead to Generic Competition
  11.5.2 New Therapies Offer an Alternative to Drug Treatment
    11.5.2.1 Neurostimulation
    11.5.2.2 Stem Cell Therapy
    11.5.2.3 Gene Therapy

12. EXPERT OPINIONS

12.1 Interview with Professor Lisa Ellerby
  12.1.1 Future Treatment Possibilities
  12.1.2 The Market Potential for a Huntington's Disease Cure
12.2 Interview with Professor Jürgen GЎtz
  12.2.1 The Obstacles for Developing a Cure for Alzheimer's Disease
  12.2.2 The Time Frame for Developing a Cure for Alzheimer's Disease
  12.2.3 Potential Alzheimer's Disease Treatments
  12.2.4 The Market Potential for a Cure for Alzheimer's Disease

13. CONCLUSIONS

13.1 Rising Prevalence Due to Aging Population to Drive Market Growth
13.2 All Markets Have Significant Unmet Needs
13.3 Pipelines for Some Diseases Are Stronger Than Others
13.4 Conclusions for Individual Market Sectors
  13.4.1 Oral Treatments Will Alter the MS Market
  13.4.2 Alzheimer's Symptom Management Therapies Will Remain Competitive
  13.4.3 Patent Expiries to Hit the Parkinson's Market
  13.4.4 Indication-Specific Drugs Will Expand the Neuropathies Market
  13.4.5 Blockbuster Potential for Novel Huntington's Drugs
  13.4.6 The ALS Market is Difficult to Predict

LIST OF TABLES

Table 2.1 Prevalence of Neurodegenerative Diseases, 2010
Table 2.2 Life Expectancy for Prion Diseases, 2010
Table 2.3 Common Causes of Neuropathies, 2010
Table 3.1 Neurodegenerative Diseases: Blockbuster Drugs, 2009
Table 3.2 World Neurodegenerative Diseases Market Forecast, 2009-2016
Table 3.3 Neurodegenerative Diseases Drivers and Restraints, 2010-2026
Table 3.4 Blockbuster Patent Expiries, 2009-2015
Table 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026
Table 4.1 Leading MS Drug Sales, 2009
Table 4.2 MS Drug Market Forecast, 2009-2016
Table 4.3 MS Drug Market Forecast, 2016-2026
Table 4.4 Selected Pipeline Treatments for MS in Phase II & III, 2010
Table 5.1 FDA Approved Alzheimer's Therapeutics, 2010
Table 5.2 Leading Alzheimer's Drug Sales, 2009
Table 5.3 Earliest Expected Approvals for Anti-Alzheimer's Treatments in Phase III, 2010
Table 5.4 Alzheimer's Drug Market Forecast, 2009-2016
Table 5.5 Alzheimer's Drug Market Forecast, 2016-2026
Table 5.6 Selected Pipeline Treatments for Alzheimer's in Phase II & III, 2010
Table 6.1 Leading Parkinson's Drug Sales, 2009
Table 6.2 Patent Expiries Affecting the Parkinson's Market, 2008-2013
Table 6.3 Parkinson's Drug Market Forecast, 2009-2016
Table 6.4 Parkinson's Drug Market Forecast, 2016-2026
Table 6.5 Stalevo & Comtess Sales, 2009
Table 6.6 Selected Pipeline Treatments for Parkinson's in Phase II & III, 2010
Table 7.1 Key Therapeutics Indicated for Neuropathies, 2010
Table 7.2 Leading Neuropathy Drug Sales, 2009
Table 7.3 Neuropathy Drug Market Forecast, 2009-2016
Table 7.4 Neuropathy Drug Market Forecast, 2016-2026
Table 7.5 The Rising Prevalence of Diabetes, 2010-2030
Table 7.6 Selected Pipeline Treatments for Neuropathies in Phase II & III, 2010
Table 8.1 Treatment Options for Huntington's, 2010
Table 8.2 Huntington's Drug Market Forecast, 2009-2016
Table 8.3 Huntington's Drug Market Forecast, 2016-2026
Table 8.4 Global Xenazine Sales, 2009
Table 8.5 Selected Pipeline Treatments for Huntington's in Phase II & III, 2010
Table 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2016
Table 9.2 ALS Drug Market: Best Case Scenario Forecast, 2016-2026
Table 9.3 ALS Drug Market: Worst Case Scenario Forecast, 2009-2016
Table 9.4 ALS Drug Market: Worst Case Scenario Forecast, 2016-2026
Table 9.5 Selected Pipeline Treatments for ALS in Phase II & III, 2010
Table 10.1 Neurodegenerative Diseases Market: National Forecasts, 2009-2016
Table 10.2 Neurodegenerative Diseases Market: National Forecasts, 2016-2026
Table 11.1 SWOT Chart for the Neurodegenerative Diseases Market, 2010-2026
Table 11.2 Population Proportions (%) Aged Over 65, 2009-2050
Table 11.3 Progress of Alternative Therapies for Neurodegenerative Diseases, 2010
Table 13.1 World Neurodegenerative Disease Market: Forecast Summary, 2009-2026

LIST OF FIGURES

Figure 2.1 The Five Stages of Parkinson's Disease
Figure 3.1 World Neurodegenerative Diseases: Market Shares by Sector, 2009
Figure 3.2 Neurodegenerative Diseases: Blockbuster Drugs, 2009
Figure 3.3 World Neurodegenerative Diseases Market Forecast, 2009-2016
Figure 3.4 World Neurodegenerative Diseases: Market Shares by Sector, 2016
Figure 3.5 World Neurodegenerative Diseases Market Forecast, 2016-2026
Figure 3.6 World Neurodegenerative Diseases: Market Shares by Sector, 2026
Figure 4.1 Leading MS Drug Sales, 2009
Figure 4.2 MS Drug Market Forecast, 2009-2016
Figure 4.3 Leading MS Drug Market Shares, 2016
Figure 4.4 Leading MS Drug Market Shares, 2026
Figure 4.5 MS Drug Market Forecast, 2016-2026
Figure 4.6 Copaxone Sales Forecast, 2009-2026
Figure 4.7 Avonex Sales Forecast, 2009-2026
Figure 4.8 Rebif Sales Forecast, 2009-2026
Figure 4.9 Betaferon Sales Forecast, 2009-2026
Figure 5.1 Leading Alzheimer's Drug Sales, 2009
Figure 5.2 Alzheimer's Drug Market Forecast, 2009-2016
Figure 5.3 Leading Alzheimer's Drugs: Market Shares, 2009, 2016 & 2026
Figure 5.4 Leading Alzheimer's Drug Market Forecast, 2016-2026
Figure 5.5 Aricept Sales Forecast, 2009-2026
Figure 5.6 Namenda Sales Forecast, 2009-2026
Figure 5.7 Exelon Sales Forecast, 2009-2026
Figure 6.1 Leading Parkinson's Drug Sales, 2009
Figure 6.2 Parkinson's Drug Market Forecast, 2009-2016
Figure 6.3 Parkinson's Drug Market Forecast, 2016-2026
Figure 6.4 Leading Parkinson's Drugs: Market Shares, 2009, 2016 & 2026
Figure 6.5 Sifrol Sales Forecast, 2009-2026
Figure 6.6 Stalevo & Comtess Sales, 2009
Figure 6.7 Stalevo & Comtess Sales Forecast, 2009-2026
Figure 6.8 Requip Sales Forecast, 2009-2026
Figure 6.9 Azilect Sales Forecast, 2009-2026
Figure 7.1 Leading Neuropathy Drug Sales, 2009
Figure 7.2 Neuropathy Drug Market Forecast, 2009-2016
Figure 7.3 Neuropathy Drug Market Forecast, 2016-2026
Figure 7.4 The Rising Prevalence of Diabetes, 2010-2030
Figure 7.5 Lyrica Sales Forecast, 2009-2026
Figure 8.1 Huntington's Drug Market Forecast, 2009-2026
Figure 8.2 Global Xenazine Sales, 2009
Figure 8.3 Xenazine Sales Forecast, 2009-2026
Figure 9.1 ALS Drug Market: Best Case Scenario Forecast, 2009-2026
Figure 9.2 ALS Drug Market: Worst Case Scenario Forecast, 2009-2026
Figure 9.3 Comparison of ALS Drug Market Scenarios, 2009, 2016 & 2026
Figure 9.4 Rilutek Sales Forecast, 2009-2026
Figure 10.1 Neurodegenerative Diseases Market: National Shares, 2009
Figure 10.2 Neurodegenerative Diseases Market: National Shares, 2016
Figure 10.3 Neurodegenerative Diseases Market: National Shares, 2026
Figure 10.4 US Market Forecast, 2009-2026
Figure 10.5 European Market Forecasts, 2009-2026
Figure 10.6 Japanese Market Forecast, 2009-2026
Figure 10.7 Chinese and Indian Market Forecasts, 2009-2026
Figure 11.1 Proportion of Population Aged Over 65 by Region, 2009-2050

Ask Your Question

Neurodegenerative Diseases: World Drug Market 2011-2026
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: